Antiretroviral therapy is associated with a decrease in unintegrated HIV-1 DNA in pediatric patients.
Good markers for monitoring the efficacy of antiretroviral therapy in children do not currently exist. This study examined the effect of antiretroviral therapy on human immunodeficiency virus (HIV-1) unintegrated DNA (uDNA), integrated DNA (iDNA), percent uDNA, immune complex dissociated (ICD) p24 antigenemia, and plasma viral titer. Seven children were followed at therapy initiation and at approximately 3- and 10-month intervals. HIV-1 uDNA was detected in all children prior to start of therapy (average percent uDNA, 43%). At 3 months, the percent HIV uDNA decreased in all patients to an average of 18% (p = 0.01) and at 10 months decreased to an average of 1%. In contrast, the amount of HIV iDNA was relatively constant after initiation of therapy. ICD HIV p24 antigen was detected in all patients prior to therapy (average, 538 pg/ml). Over the study period, the ICD p24 antigen level decreased in three patients and remained relatively unchanged in four patients. Plasma cultures of HIV-1 were positive in only one of the seven patients prior to therapy. Among the methods evaluated, measurement of uDNA was the only parameter which reliable decreased after initiation of nucleoside therapy.
Department of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan 48202.
R M
RM
Donovan
C E
CE
Bush
S M
SM
Smereck
E
E
Moore
F
F
Cohen
L D
LD
Saravolatz
D018791:CD4 Lymphocyte Count; D002675:Child, Preschool; D004279:DNA, Viral / Q000097:blood*; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016655:HIV Core Protein p24 / Q000097:blood; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007223:Infant; D007963:Leukocytes, Mononuclear / Q000821:virology; D008297:Male; D016133:Polymerase Chain Reaction; D014766:Viremia / Q000821:virology; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use*
D004279:DNA, Viral; D016655:HIV Core Protein p24; D015215:Zidovudine; D016049:Didanosine